<DOC>
	<DOCNO>NCT02424396</DOCNO>
	<brief_summary>Interleukin‐2 ( IL‐2 ) initially discover used stimulator effector T lymphocytes ( Teffs ) , view promising immunoregulatory drug capacity stimulate regulatory T cell ( Tregs ) . At low dose , Il-2 tip Treg/Teff balance towards Tregs . Recently , show Tregs MS patient reduce proliferative potential . MS-IL2 assess safety biological efficacy low-dose IL2 Treg inducer Relapsing-Remitting Multiple Sclerosis ( RRMS ) , aim stimulate Treg define potential clinical benefit</brief_summary>
	<brief_title>Biological Activity Safety Low Dose IL2 Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description>In MS-IL2 , 30 RRMS patient treat randomized , double-blind , placebo control clinical trial . IL‐2 administer first induction course IL-2 placebo day 5 day , follow maintenance course dose placebo every two week 6 month . The primary efficacy criterion % change baseline Treg day‐5 , indicative biological response IL‐2 . The secondary efficacy criterion ( ) maintenance regulatory T cell 6 month treatment IL-2 vs. placebo ( ii ) stabilization regression disease determine disease activity parameter assess MRI ( cumulative number new lesion T1 enhance gadolinium 6 month ) group treat IL-2 compare placebo . Expected impact : MS-IL2 define patient respond IL2 dose prevent relapse RRMS . In addition , deep phenomics study provide foundation clinical phase II define clinical efficacy .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Age 1865 year old ; Male Female ; Presenting relapse remit multiple sclerosis determine revise McDonald criterion ( 2010 ) ; On MRI : 1 ) Presenting 12 lesion enhance gadolinium ( Gd+ ) ( T1 ) without clinical expression disease clinique upon inclusion 6 month prior inclusion 2 ) present one new lesion T2 Expanded Disability Status Scale ( EDSS ) score comprise 0 6 ; Under βInterferon treatment ≥ 12 month ; For woman childbearing age , contraception 2 week upon confirmation inclusion criterion negative Beta HCG inclusion visit ( D30 D7 ) ; Patient inform consent sign patient investigator perform clinical examination require study . Affiliation French Social Security Regimen Number lesion enhance gadolinium ( Gd+ ) MRI T1 &gt; 2 upon inclusion ; Known intolerance IL2 ( see SPC ) : Hypersensibility active substance one excipients ; Signs evolve infection require treatment Other clinically significant chronic disorder ( beside RRMS ) History organ allograft Administration nonauthorized treatment ; bolus corticosteroid last 30 day , immunosuppressive ou immunomodulatory treatment ( exclude βinterferon treatment ) last 24 month ; Heart failure ( ≥ grade III NYHA ) , renal insufficiency , hepatic insufficiency ( transaminase &gt; 5N ) , lung failure White blood cell count &lt; 4000 /mm3 , lymphocytes &lt; 1200 /mm3 , platelet &lt; 150 000 /mm3 Poor venous access allow repeat blood test Vaccination live attenuate virus month precede inclusion plan study Surgery last 2 month surgery plan study Participation biomedical research last one month plan study Concomitant psychiatric disease chronic illness drugabuse could interfere ability comply protocol give inform consent Cancer history cancer cure less five year ( except situ carcinoma cervix basocellular carcinoma ) Pregnant lactate woman ; Patients measure legal protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Interleukin 2 , IL2</keyword>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>Autoimmune disease</keyword>
	<keyword>Regulatory T cell , Tregs</keyword>
</DOC>